Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Teva
Chinese Patent Office
Johnson and Johnson
AstraZeneca
Dow
McKesson
Healthtrust
Citi
US Department of Justice

Generated: February 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,114,068

« Back to Dashboard

Summary for Patent: 9,114,068
Title:Treating patients with intravenous ibuprofen
Abstract: Methods of treating a patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen in an amount effective to treat at least one condition in the patient chosen from pain, inflammation, and fever and to provide a clinically relevant effect on mean arterial pressure of the patients during the dosage interval comprising no increase or no statistically significant increase in mean arterial pressure.
Inventor(s): Pavliv; Leo (Cary, NC), Rock; Amy Dix (Thompson Station, TN)
Assignee: Cumberland Pharmaceuticals, Inc. (Nashville, TN)
Application Number:14/264,267
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Drugs Protected by US Patent 9,114,068

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Cumberland Pharms CALDOLOR ibuprofen SOLUTION;INTRAVENOUS 022348-002 Jun 11, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up METHODS OF TREATING PAIN, INFLAMMATION AND/OR FEVER WITH INTRAVENOUS IBUPROFEN SUCH THAT MEAN ARTERIAL BLOOD PRESSURE DOES NOT INCREASE THE DOSAGE INTERVAL ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,114,068

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,735,452 Treating patients with intravenous ibuprofen ➤ Sign Up
9,295,639 Treating critically ill patients with intravenous ibuprofen ➤ Sign Up
9,649,284 Treating critically ill patients with intravenous ibuprofen ➤ Sign Up
8,871,810 Treating critically ill patients with intravenous ibuprofen ➤ Sign Up
9,138,404 Treating critically ill patients with intravenous ibuprofen ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,114,068

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan 2012533542 ➤ Sign Up
Japan 5837877 ➤ Sign Up
European Patent Office 2458988 ➤ Sign Up
European Patent Office 2515906 ➤ Sign Up
Japan 2013500964 ➤ Sign Up
South Korea 20120089444 ➤ Sign Up
European Patent Office 2453742 ➤ Sign Up
South Korea 20120089623 ➤ Sign Up
South Korea 20120138229 ➤ Sign Up
China 102791268 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Chubb
Harvard Business School
McKesson
Cerilliant
Deloitte
Johnson and Johnson
Federal Trade Commission
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot